Insider Buying: Mesoblast Limited (ASX:MSB) Insider Purchases 233,918 Shares of Stock

Mesoblast Limited (ASX:MSB) insider Jane Bell purchased 233,918 shares of the stock in a transaction on Friday, April 12th. The stock was bought at an average price of A$0.86 ($0.55) per share, for a total transaction of A$199,999.89 ($129,032.19).

Mesoblast Price Performance

The company has a quick ratio of 1.82, a current ratio of 2.71 and a debt-to-equity ratio of 23.98.

About Mesoblast

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.